Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

Performances in N.Y.C. Advertisement Supported by Elim Chan has been named the symphony’s next music director. She joins a small field of female conductors at American orchestras, as San Francisco ...

WASHINGTON, May 11 (Reuters) - High-profile short seller Andrew Left's criminal trial will kick off in Los Angeles this week, spotlighting a contentious cohort of investors who have for years ‌goaded ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

VANCOUVER, British Columbia (CTV) - Authorities say speed is believed to have been a factor in a crash that left a motorcycle hanging off a traffic light in Canada. The crash between a car and a ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

THIS PROPOSAL. STACEY. KAYLA. THANK YOU. STARTS RIGHT HERE. A YOUTH EDUCATIONAL AND OUTREACH PROGRAM IN DES MOINES IS EXPANDING. FOUNDER WILL KEEP SAYS STARTS RIGHT HERE. WILL PURCHASE THE FORMER ELIM ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Causes of lower left back pain include injuries, infections, and underlying conditions. You can manage your pain by using careful preventive measures, getting a timely diagnosis, and following a ...

Let me be honest with you: I am not the target audience for modern dating. I've tried the apps. I've done the prompts. I've stared at a Bumble profile for twenty minutes and felt absolutely nothing.

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.